Lake Zurich-based Fresenius Kabi Thursday announced the immediate availability in the U.S. of Stimufend, a drug similar to Neulasta, for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications.
Related posts
-
Authorities believe crash through Illinois after-school building that killed 4 wasn’t targeted
Three children and a teenager were killed and others were injured when a car drove through... -
United’s refreshed Polaris Lounge features more space, new decor and dining options
A second bar, Crate & Barrel ambiance and extra legroom await international business travelers. -
Engines of change: Chicago program puts young minds on the fast track to STEM
Chicago Pre-College Science and Engineering Program offers enrichment classes for historically underrepresented students.